APL 4.17% 12.5¢ associate global partners limited

chronic lung disease

  1. PSH
    278 Posts.
    Exciting news ahead -
    ?
    ?
    ?We have made major advances in understanding the market opportunities in COPD diagnosis and forged new clinical relationships and collaborations (both within Australia and internationally) through participation in key respiratory disease meetings, including the Thoracic Society ANZ in Perth and the American Thoracic Society Meeting in Denver, USA.
    ?
    Bringing all of the above developments together, we are currently sourcing and testing a range of clinical samples that should define Tyrian?s first proprietary point-of-care test got chronic lung disease".
 
watchlist Created with Sketch. Add APL (ASX) to my watchlist
(20min delay)
Last
12.5¢
Change
0.005(4.17%)
Mkt cap ! $7.061M
Open High Low Value Volume
12.5¢ 12.5¢ 12.5¢ $1.25K 10K

Buyers (Bids)

No. Vol. Price($)
1 17597 12.0¢
 

Sellers (Offers)

Price($) Vol. No.
13.5¢ 48000 1
View Market Depth
Last trade - 10.35am 19/07/2024 (20 minute delay) ?
APL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.